CTOs on the Move

Gyroscope Therapeutics

www.gyroscopetx.com

 
Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. The company was acquired by Novartis, a leading global medicines company, in February 2022.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.gyroscopetx.com
  • 2200 Renaissance Boulevard Suite 410
    King of Prussia, PA USA 19406
  • Phone: 267.523.2100

Executives

Name Title Contact Details

Similar Companies

Seventh Wave

Seventh Wave is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Century Therapeutics

Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.

Boston Immune Technologies and Therapeutics

Boston Immune Technologies & Therapeutics based Inc

Morphosys USA

Morphosys USA, Inc. is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lineage Cell

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.